ImmunoGen Message Board - Msg: 28610493

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen

IMGN 31.23

0.0%

Feb 26 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: rjk01 who wrote (5520)	12/17/2012 3:52:56 PM
From: Gary Mohilner	of 5665

I do expect over $20 on approval, but perhaps not immediately. I certainly don't believe it will stop at $20. Look at all the trials T-DM1 is in, and consider how many more may come in the future, and I think you'll agree that T-DM1 could earn well over what Herceptin does, and that's currently about $6 billion a year. At $10 billion annually IMGN will earn over $400 million, roughly $4 a share. Any reasonable P/E should be at least $40, and perhaps as much as $120 on a P/E of 30 if other milestone payments and earnings from partnerships offset other company costs. Gary

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next